Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1779837

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1779837

Comprehensive Metabolic Panel Testing

PUBLISHED:
PAGES: 385 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Comprehensive Metabolic Panel Testing Market to Reach US$18.1 Billion by 2030

The global market for Comprehensive Metabolic Panel Testing estimated at US$11.5 Billion in the year 2024, is expected to reach US$18.1 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Glucose, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Creatinine segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 12.4% CAGR

The Comprehensive Metabolic Panel Testing market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Comprehensive Metabolic Panel Testing Market - Key Trends & Drivers Summarized

Why Is Comprehensive Metabolic Panel Testing Becoming Increasingly Important?

Comprehensive metabolic panel testing has become a critical tool in modern healthcare, providing valuable insights into overall metabolic function, organ health, and electrolyte balance. This blood test, which measures glucose levels, kidney function, liver enzymes, and electrolyte imbalances, is widely used for routine health check-ups, chronic disease management, and preoperative assessments. With the rising prevalence of metabolic disorders, kidney diseases, and liver conditions, the demand for CMP testing is steadily increasing across hospitals, diagnostic laboratories, and outpatient clinics. The growing global burden of diabetes and cardiovascular diseases has been a major driver for CMP testing adoption. Early detection of metabolic abnormalities allows healthcare providers to diagnose and manage conditions such as diabetes mellitus, hypertension, and kidney dysfunction before they progress into severe complications. Additionally, with the increasing geriatric population, the need for regular metabolic assessments has risen, as older individuals are at higher risk for multiple chronic conditions that require continuous monitoring. Another significant factor driving CMP testing demand is the expansion of preventive healthcare initiatives worldwide. Governments and healthcare organizations are actively promoting regular health screenings to reduce the incidence of non-communicable diseases. Corporate wellness programs and health insurance providers are also incentivizing routine blood tests, leading to an increase in CMP testing volumes. As healthcare systems shift from reactive to preventive approaches, comprehensive metabolic panels are playing a crucial role in proactive patient care.

How Are Technological Advancements Enhancing the Accuracy and Efficiency of CMP Testing?

The evolution of diagnostic technologies has significantly improved the accuracy, speed, and accessibility of comprehensive metabolic panel testing. The introduction of automated biochemical analyzers has revolutionized clinical laboratories, enabling faster and more precise testing with minimal human intervention. These advancements have reduced turnaround times, allowing for quicker diagnosis and treatment decisions. Additionally, improvements in reagent formulations and assay standardization have enhanced the reliability of metabolic panel results, ensuring greater diagnostic accuracy. Point-of-care testing (POCT) is another major technological development that is transforming the CMP testing landscape. Portable and handheld biochemical analyzers now allow for on-the-spot metabolic assessments in emergency rooms, outpatient clinics, and even home settings. The ability to obtain rapid results without requiring traditional laboratory infrastructure has improved patient convenience and streamlined clinical workflows, particularly in critical care scenarios where timely intervention is crucial. The integration of artificial intelligence (AI) and machine learning in diagnostic laboratories is further optimizing CMP testing efficiency. AI-powered data analytics platforms are being used to identify trends, flag abnormal results, and provide predictive insights into metabolic health. These technologies are aiding physicians in early disease detection and risk assessment, improving patient outcomes. Moreover, the digitization of lab results through electronic health records (EHR) is enhancing data accessibility and enabling better patient-provider collaboration in managing metabolic conditions.

What Market Trends Are Driving the Growth of CMP Testing?

One of the most notable trends shaping the comprehensive metabolic panel testing market is the increasing adoption of at-home diagnostic solutions. The rise of direct-to-consumer (DTC) testing services has empowered individuals to take charge of their health by ordering CMP tests without the need for physician referrals. Online health platforms and telemedicine providers are offering home-based blood collection kits, allowing users to submit samples for laboratory analysis and receive digital results. This trend is particularly gaining traction among tech-savvy consumers who prioritize convenience and preventive healthcare. The expansion of diagnostic laboratory networks and strategic partnerships is also fueling market growth. Leading diagnostic service providers are expanding their footprints by opening new testing facilities and forming collaborations with hospitals and clinics. These partnerships are ensuring wider accessibility to CMP testing, particularly in underserved regions where advanced diagnostic services were previously limited. Additionally, multinational diagnostic companies are investing in emerging markets, recognizing the growing demand for metabolic screening in developing countries. Regulatory efforts to improve laboratory quality standards and test reimbursement policies are further shaping market dynamics. Many countries are implementing stringent guidelines to ensure the accuracy and reliability of biochemical testing, fostering trust in diagnostic services. At the same time, health insurance coverage for routine blood tests, including CMPs, is improving in several regions, making these tests more affordable and accessible to a larger patient population. As healthcare payers recognize the cost-saving benefits of early disease detection, coverage policies for preventive metabolic screening are expected to expand.

What Are the Key Growth Drivers Fueling the Market?

The growth in the comprehensive metabolic panel testing market is driven by several factors, including advancements in diagnostic automation, increasing chronic disease prevalence, and the expansion of point-of-care testing solutions. One of the primary growth drivers is the rising incidence of metabolic disorders, particularly diabetes, obesity, and kidney disease. As these conditions become more widespread, regular metabolic assessments are becoming essential for disease monitoring and management, leading to higher testing volumes. The increasing adoption of digital health solutions is another major factor contributing to market expansion. Telemedicine platforms are integrating CMP testing into virtual care models, enabling remote patient monitoring and enhancing chronic disease management. Digital health companies are partnering with laboratories to offer seamless online test ordering and result delivery, making metabolic panel testing more convenient and accessible. The convergence of diagnostics and digital health is expected to drive continued adoption of CMP testing in both clinical and home settings. The expansion of healthcare infrastructure in emerging economies is also playing a crucial role in market growth. Developing countries are witnessing increased investments in diagnostic laboratories and hospital facilities, improving access to routine health screenings. Governments in these regions are launching public health initiatives to promote early disease detection, further driving demand for CMP testing. Additionally, the rising disposable incomes and growing health consciousness in emerging markets are encouraging individuals to seek preventive healthcare services, contributing to the overall market expansion. Furthermore, ongoing research and development efforts aimed at enhancing biomarker detection in metabolic panel testing are expected to open new growth opportunities. Scientists are exploring novel biomarkers that can provide deeper insights into metabolic health, enabling more precise risk assessment and personalized treatment plans. As diagnostic capabilities continue to evolve, the comprehensive metabolic panel testing market is poised for sustained growth, driven by technological innovation, expanding healthcare access, and the increasing emphasis on preventive medicine.

SCOPE OF STUDY:

The report analyzes the Comprehensive Metabolic Panel Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Analytes (Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin, Other Analytes); Disease (Kidney Diseases, Diabetes, Liver Diseases, Other Diseases); End-Use (Laboratories End-Use, PoC End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • American Esoteric Laboratories
  • ARUP Laboratories
  • Baptist Health Medical Group
  • CENTOGENE N.V.
  • Charles River Laboratories Inc.
  • Genoptix Inc.
  • LabCorp Drug Development
  • Laboratory Corporation of America Holdings (LabCorp)
  • Laboratory Services of America
  • NeoGenomics Laboratories, Inc.
  • Nova Medical
  • Quest Diagnostics
  • Scion Lab Services LLC
  • Siemens Healthcare GmbH
  • Sonic Healthcare
  • SYNLAB International GmbH
  • TCG Corp.
  • UNIPATH
  • Walk-In Lab, LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP30150

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Comprehensive Metabolic Panel Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Preventive Healthcare and Routine Screening Drives Demand for Metabolic Panel Testing
    • Expansion of Wellness Programs and Annual Health Check-Ups Fuels Clinical Adoption
    • OEM Integration With Lab Information Systems and EHR Enhances Test Ordering and Reporting Efficiency
    • Growing Use in Chronic Disease Management Programs Supports Repeat and Panelized Testing
    • Increased Use in Preoperative Evaluations and Baseline Assessments Enhances Test Frequency
    • OEM Development of Automated and High-Throughput Analyzers Supports Laboratory Efficiency
    • Growing Role of Telemedicine and At-Home Sample Collection Expands Access to Testing
    • OEMs Offering Multiplexed Assays and Expanded Biomarker Panels Improve Diagnostic Value
    • Rising Utilization in Monitoring Liver, Kidney, and Electrolyte Function Across Age Groups Broadens Application
    • OEMs Supporting Customizable Panel Configurations Enable Use in Specialized Clinical Settings
    • Growth in Corporate Wellness and Occupational Health Screening Programs Drives Institutional Demand
    • OEM Collaborations With Diagnostic Labs and Clinics Expand Geographic and Segment Reach
    • Increased Insurance Coverage and Employer Reimbursement Models Encourage Test Utilization
    • OEMs Offering Integration With Decision Support Tools Improve Interpretation and Clinical Actionability
    • Rise in Point-of-Care Testing and Rapid Diagnostic Platforms Enhances Speed of Diagnosis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Comprehensive Metabolic Panel Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Glucose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Glucose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Glucose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Creatinine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Creatinine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Creatinine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ca++ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ca++ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ca++ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for ALT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for ALT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for ALT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for BUN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for BUN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for BUN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for K+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for K+ by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for K+ by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Total Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Total Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Total Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Total Bilirubin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Total Bilirubin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Total Bilirubin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Analytes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Analytes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Analytes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Kidney Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Kidney Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Kidney Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for PoC End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for PoC End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for PoC End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 125: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Spain 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Russia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Australia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 182: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 188: India Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: India 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: South Korea 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Argentina 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Brazil 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Mexico 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Iran 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Israel 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: UAE 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Comprehensive Metabolic Panel Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Comprehensive Metabolic Panel Testing by Analytes - Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by Analytes - Percentage Breakdown of Value Sales for Glucose, Creatinine, Ca++, ALT, BUN, K+, Total Protein, Total Bilirubin and Other Analytes for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Comprehensive Metabolic Panel Testing by Disease - Kidney Diseases, Diabetes, Liver Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by Disease - Percentage Breakdown of Value Sales for Kidney Diseases, Diabetes, Liver Diseases and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Comprehensive Metabolic Panel Testing by End-Use - Laboratories End-Use and PoC End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Africa 15-Year Perspective for Comprehensive Metabolic Panel Testing by End-Use - Percentage Breakdown of Value Sales for Laboratories End-Use and PoC End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!